Invention Grant
- Patent Title: Pharmaceutical composition comprising neptinib or salt thereof and method for controlling impurity thereof
-
Application No.: US16330337Application Date: 2017-09-01
-
Publication No.: US10668069B2Publication Date: 2020-06-02
- Inventor: Jingan Yang , Zhiguo Wang , Jing Cui , Xiaorou Liu
- Applicant: SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD.
- Applicant Address: CN Shenzhen, Guangdong
- Assignee: SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSITUTE CO., LTD
- Current Assignee: SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSITUTE CO., LTD
- Current Assignee Address: CN Shenzhen, Guangdong
- Agency: Greer, Burns & Crain, Ltd.
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@6bbd9a78
- International Application: PCT/CN2017/100189 WO 20170901
- International Announcement: WO2018/041246 WO 20180308
- Main IPC: A61K31/517
- IPC: A61K31/517 ; A61K9/00 ; A61K47/36 ; A61K47/38 ; A61K47/12 ; A61K47/14 ; A61P35/00 ; A61K47/26 ; A61K9/20 ; A61K9/28
Abstract:
A pharmaceutical composition including neptinib is provided. The composition includes neptinib or a pharmaceutically acceptable salt thereof, and an excipient at a low risk of compatibleness. Furthermore, the pharmaceutical composition of the present invention may also include pharmaceutically acceptable organic acid or inorganic acid as a stabilizer. The content of impurity A maintains a non-significant increase in the long-term and accelerated stability investigation for the pharmaceutical composition.
Public/Granted literature
Information query
IPC分类:
